U.S. National Security Infrastructure
Atlantic Shield is building sovereign U.S. pharmaceutical manufacturing capability — from raw ingredient synthesis through finished injectable dosage forms — anchored in Puerto Rico.
The Vulnerability
The United States depends on foreign sources — predominantly China and India — for the vast majority of the active pharmaceutical ingredients in its most essential hospital medicines. Sterile injectables, IV antibiotics, vasopressors, anesthetics, and nerve agent antidotes all trace back to a handful of offshore suppliers. In a peer-adversary conflict or trade disruption, these medications could become unavailable within weeks.
This is not a commercial problem. It is a national security emergency.
Key Starting Materials & API synthesis
Formulation & finished dosage manufacturing
Military & civilian end users
SINGLE POINT OF FAILURE
One geopolitical decision can sever the entire chain
Flagship Operating Entity
Atlantic Shield Pharma is building an integrated domestic manufacturing corridor — from raw API synthesis through sterile fill-finish — capable of producing the critical injectable medicines that today depend almost entirely on foreign sources. The program covers the full pharmaceutical vertical â from active ingredient synthesis through finished dosage forms.
Domestic production of active ingredients across multiple complexity tiers, including controlled substances and high-potency compounds.
GMP-compliant finished dosage manufacturing — vials, ampoules, pre-filled syringes, and auto-injectors for battlefield deployment.
Pre-positioned bridge supply to provide immediate coverage while domestic production ramps to full capacity.
FDA-regulated, DEA-licensed operations with continuous GMP compliance and integrated quality management systems.
Mobilization Approach
The program follows a three-phase mobilization timeline modeled on established defense industrial base precedents — the same approach used in Operation Warp Speed and BARDA domestic API initiatives.
Site activation, tech transfer, CDMO qualification, security stockpile pre-positioning, and auto-injector production line.
Domestic API lines operational, sterile fill-finish at commercial scale, raw material sourcing diversified across allied and domestic sources.
Complete domestic API-to-FPP vertical integration, full production capacity, surge readiness for conflict scenarios.
Other Transaction Authority — the same rapid-mobilization contracting vehicle behind Operation Warp Speed and other defense prototype programs.
Defense Production Act authority for direct investment in domestic production capacity — the foundation for $1.6B+ in industrial base expansion since 2020.
Manufacturing tax incentives that structurally improve program economics and reduce the cost of domestic pharmaceutical production.
Strategic Location
Puerto Rico is the only U.S. jurisdiction that combines legacy pharmaceutical manufacturing infrastructure, a trained workforce, Jones Act-compliant maritime logistics, federal regulatory jurisdiction, and available former military installations at scale.
At its peak, Puerto Rico produced approximately 25% of all FDA-approved drugs by value — an institutional foundation no mainland greenfield site can replicate.
DEA-licensed facilities and established pharmaceutical corridors ready for reactivation — years ahead of greenfield construction timelines.
Security-clearance eligible. Legacy of 90+ pharmaceutical manufacturing facilities on the island. Trained talent pool in GMP operations, quality, and regulatory affairs.
Controlled, traceable domestic supply chain to CONUS. Foreign-origin raw materials import directly to Puerto Rico without Jones Act cost premiums.
Available campus-scale footprints across the island provide the acreage and security perimeter for defense-grade manufacturing and secure operations.
The Enterprise
Atlantic Shield Enterprise is the parent holding company for a family of national security infrastructure businesses. While Atlantic Shield Pharma is the active flagship program, the enterprise is structured to address multiple dimensions of U.S. strategic vulnerability — all anchored in Puerto Rico.
Defense-critical manufacturing cannot depend on fragile commercial power grids. Atlantic Shield Energy is building dedicated, islandable microgrids with hardened on-site generation, black-start capability, and Category 5 hurricane resilience — designed to operate independently when the grid cannot.
Hardened Tier III federal data centers and AI compute infrastructure deployed at former military installations in Puerto Rico. Atlantic Shield Data serves the Department of Defense cloud ecosystem, powers AI-driven drug discovery and clinical modeling for the pharma mission, and provides secure national security compute on U.S. soil with U.S. citizens.
All three pillars are structurally interdependent — Energy powers Pharma and Data, Data accelerates Pharma R&D, and guaranteed compute offtake makes dedicated generation financially viable. This is one integrated national security infrastructure program.
Contact
807 Ave. Ponce de León, PMB 0122
San Juan, Puerto Rico 00907-3326
Atlantic Shield Enterprise is a Delaware LLC headquartered in San Juan, Puerto Rico. Operating subsidiaries — Atlantic Shield Pharma, LLC; Atlantic Shield Energy, LLC; and Atlantic Shield Data, LLC — are Puerto Rico LLCs. The enterprise operates as a national security infrastructure program in partnership with the United States Department of War under established federal contracting authorities.